Literature DB >> 11600585

The postmenopausal ovary is not a major androgen-producing gland.

B Couzinet1, G Meduri, M G Lecce, J Young, S Brailly, H Loosfelt, E Milgrom, G Schaison.   

Abstract

It is currently believed that the postmenopausal ovary remains a gonadotropin-driven, androgen-producing gland. However, the adrenal contribution to circulating androgen levels may explain some conflicting results previously reported. In addition, the steroidogenic potential and gonadotropin responsiveness of the postmenopausal ovary have not been recently reassessed. Plasma T, bioavailable T, free T, androstenedione (Adione), and dehydroepiandrosterone sulfate levels were measured in postmenopausal or ovariectomized women with complete adrenal insufficiency, compared with women with intact adrenals. A stimulation human chorionic gonadotropin test (on d 0, 3, and 6) was performed in postmenopausal women with adrenal insufficiency. Dexamethasone was administered for 4 d in postmenopausal women with intact adrenals. Intraovarian T and androstenedione were also measured in homogenates of ovarian tissue from postmenopausal women. Immunocytochemistry was performed on postmenopausal ovaries and premenopausal controls to detect the presence of steroidogenic enzymes (P-450 aromatase, P-450 SCC, 3beta HSD, and P-450 C17) and gonadotropin receptors. Plasma androgen levels were below or close to the limit of the assay in all women with adrenal insufficiency. They were similar in postmenopausal and oophorectomized women with normal adrenals. No hormonal changes were observed after human chorionic gonadotropin injections in women with adrenal insufficiency. In contrast, a dramatic decrease of all steroids was observed after dexamethasone administration in postmenopausal women with intact adrenals. Intraovarian T and androstenedione levels were negligible in postmenopausal ovarian tissue. P-450 aromatase was absent from the 17 ovaries studied, and the enzymes for androgen biosynthesis were either absent (n = 13) or present in very low amounts (n = 4). In all the postmenopausal ovaries, FSH and LH receptors were completely absent. In the absence of adrenal steroids, postmenopausal women have no circulating androgens. This result is consistent with the immunocytochemical studies showing the almost constantly absent steroidogenic enzymes and LH receptors in the postmenopausal ovary. Thus, the climacteric ovary is not a critical source of androgens. The arrest of androgen secretion after menopause may impact significantly on women's health.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11600585     DOI: 10.1210/jcem.86.10.7900

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

Review 1.  Circulating androgens in women: exercise-induced changes.

Authors:  Carina Enea; Nathalie Boisseau; Marie Agnès Fargeas-Gluck; Véronique Diaz; Benoit Dugué
Journal:  Sports Med       Date:  2011-01-01       Impact factor: 11.136

2.  Human adrenal cells that express both 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) and cytochrome b5 (CYB5A) contribute to adrenal androstenedione production.

Authors:  Yasuhiro Nakamura; Yewei Xing; Xiao-Gang Hui; Yumi Kurotaki; Katsuhiko Ono; Tony Cohen; Hironobu Sasano; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2010-12-23       Impact factor: 4.292

3.  Dehydroepiandrosterone sulfate levels reflect endogenous luteinizing hormone production and response to human chorionic gonadotropin challenge in older female macaque (Macaca fascicularis).

Authors:  Francisco M Moran; Jiangang Chen; Nancy A Gee; Pete N Lohstroh; Bill L Lasley
Journal:  Menopause       Date:  2013-03       Impact factor: 2.953

Review 4.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

Review 5.  The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.

Authors:  Alexander T Faje; Anne Klibanski
Journal:  Endocrine       Date:  2014-06-03       Impact factor: 3.633

6.  Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer.

Authors:  Kate Lawrenson; Barbara Grun; Elizabeth Benjamin; Ian J Jacobs; Dimitra Dafou; Simon A Gayther
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

Review 7.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 8.  Sex hormones and mood in the perimenopause.

Authors:  Peter J Schmidt; David R Rubinow
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

9.  Steroidogenic capacity of residual ovarian tissue in 4-vinylcyclohexene diepoxide-treated mice.

Authors:  Zelieann Rivera; Patricia J Christian; Sam L Marion; Heddwen L Brooks; Patricia B Hoyer
Journal:  Biol Reprod       Date:  2008-10-01       Impact factor: 4.285

10.  Retaining Residual Ovarian Tissue following Ovarian Failure Has Limited Influence on Bone Loss in Aged Mice.

Authors:  Zelieann R Craig; Samuel L Marion; Janet L Funk; Mary L Bouxsein; Patricia B Hoyer
Journal:  J Osteoporos       Date:  2010-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.